Philips’ has recalled a number of high profile medical devices in recent years, shaking investor confidence.
Musk announced Neuralink’s first sucessful human BCI implant on Sunday, but can the company live up to the hype?
As the deadline nears for the government to reveal its proposed prices, pharmaceutical companies are continuing to fight regulation.
A US court has granted the FTC’s request to halt the acquisition due to concerns that it will promote anticompetitive practices.
The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence platform.
Give your business an edge with our leading industry insights.
Both the European Commission and the US’ Federal Trade Commission have taken issue with Illumina’s reacquisition of Grail.
A study shared at ASH saw lupus and sclerosis patients make marked recoveries through CAR-T therapy initally targeted at blood cancers.
The plans would allow third parties to manufacture such drugs if manufacturers make them unaffordable.
The collaboration focuses on the evaluation of real-world data study designs and methods for informing regulatory objectives.
Generative AI, particularly GPT-4, is capable of producing fake data sets in minutes. A new paper shows just how bad this could be.